Lead Product(s) : Triazolam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects
Details : Triazolam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : Triazolam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triazolam
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Life Receives Final USFDA Approval for Insomnia Drug
Details : Halcion (triazolam) tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep). It works by slowing activity in the brain to allow sleep.
Product Name : Triazolam-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 30, 2022
Lead Product(s) : Triazolam
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triazolam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Triazolam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 22, 2011
Lead Product(s) : Triazolam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
